What is Zai Lab?
Established in 2014 and headquartered in Shanghai, China, Zai Lab operates as a bio-pharmaceutical and drug discovery entity with a strategic focus on oncology and autoimmune diseases. The company is dedicated to identifying, developing, and commercializing innovative therapies to address unmet medical needs. Its operations span research and development through to clinical trials and market access, positioning it as a key player in China's rapidly evolving healthcare landscape. Zai Lab's commitment to scientific rigor and therapeutic innovation drives its mission to improve patient outcomes.
How much funding has Zai Lab raised?
Zai Lab has raised a total of $1.4B across 6 funding rounds:
Series A
$30M
Series B
$100M
Series C
$30M
Stock Offering
$150M
Share Placement
$261.3M
Stock Offering
$825M
Series A (2014): $30M with participation from Steamboat Ventures, Kleiner Perkins, Qiming Venture Partners, and TF Capital
Series B (2016): $100M led by TF Capital, Qiming Venture Partners, OrbiMed, Steamboat Ventures, and Advantech Capital
Series C (2017): $30M supported by Cormorant Asset Management, Rock Springs Capital, OrbiMed, and Vivo Capital
Stock Issuance/Offering (2017): $150M, investors not publicly disclosed
Share Placement (2020): $261.3M, investors not publicly disclosed
Stock Issuance/Offering (2020): $825M, investors not publicly disclosed
Key Investors in Zai Lab
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services, bringing together investment professionals with extensive experience in life sciences and healthcare business development.
Steamboat Ventures
Steamboat Ventures, founded in 2000, focuses on helping young companies become market leaders. They invest in early to growth stage companies within the technology, media, and consumer sectors. The firm is dedicated to creating lasting value in each of its investments. Their approach emphasizes a commitment to nurturing and supporting the growth of their portfolio companies.
Qiming Venture Partners
Qiming Venture Partners is a leading investment firm in China, focusing on healthcare and technology sectors. The firm backs innovative companies at various stages of growth, providing strategic guidance and capital to help them achieve market leadership.
What's next for Zai Lab?
The substantial enterprise-level funding and recent strategic investment indicate Zai Lab is in a significant growth phase, likely focused on scaling its operations, advancing its clinical pipeline, and potentially expanding its global reach. This capital infusion is critical for navigating the complex and lengthy drug development process, from late-stage clinical trials to regulatory approvals and commercialization. The company's strategic focus on oncology and autoimmune diseases suggests continued investment in these high-impact therapeutic areas, aiming to bring novel treatments to market and solidify its position as a leader in biopharmaceutical innovation.
See full Zai Lab company page
